Plasma N-acylethanolamine and endocannabinoid levels in burning mouth syndrome: Potential role in disease pathogenesis.
J Oral Pathol Med
; 47(4): 440-442, 2018 Apr.
Article
en En
| MEDLINE
| ID: mdl-29436743
ABSTRACT
OBJECTIVE:
The objective was to measure endocannabinoid (eCB) ligands and non-cannabinoid N-acylethanolamine (NAE) molecules in plasma from individuals with burning mouth syndrome (BMS) and to determine whether plasma eCB/NAE levels correlated with pain, inflammation and depressive symptomatology in this cohort. STUDYDESIGN:
Plasma content of the eCBs, anandamide (AEA) and 2-arachidonoyl-glycerol (2-AG), and the NAE molecules, palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) were assessed in healthy subjects (n = 8) and in a cohort of newly diagnosed BMS patients (n = 9) using liquid chromatography-tandem mass spectrometry. Plasma eCBs and NAE profiles were correlated with self-rated oral cavity pain intensities, depressive symptomatology and plasma IL-8 levels.RESULTS:
Plasma levels of PEA, but not OEA, AEA or 2-AG, were significantly elevated in patients with BMS, when compared to plasma from healthy individuals. Plasma PEA, OEA and AEA levels correlated with depressive symptomatology.CONCLUSIONS:
This is the first evidence to indicate that circulating eCB/NAE levels are altered in BMS.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Síndrome de Boca Ardiente
/
Endocannabinoides
/
Etanolaminas
Tipo de estudio:
Etiology_studies
/
Observational_studies
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
J Oral Pathol Med
Asunto de la revista:
ODONTOLOGIA
/
PATOLOGIA
Año:
2018
Tipo del documento:
Article
País de afiliación:
Irlanda